O
VTGN icon

OrbiMed’s VistaGen Therapeutics VTGN Stock Holding History

OrbiMed’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,200
Closed -$29.9K – 133
2025
Q4 		$29.9K Hold
45,200
– – ﹤0.01% 107
2025
Q3 		$160K Buy
+45,200
New +$135K ﹤0.01% 109

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

OrbiMed's VTGN Position: Q1 2026 in Review

OrbiMed held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 3,060,000 shares worth $1.75M. The position accounts for 0.03% of the portfolio, ranked #109.

OrbiMed first reported a position in VTGN in Q4 2020 and has held it in 10 quarters since. The position peaked at $45.6M in Q2 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • OrbiMed held 3,060,000 shares of VistaGen Therapeutics worth $1.75M as of Q1 2026.
  • OrbiMed left its VistaGen Therapeutics share count unchanged in Q1 2026.
  • VistaGen Therapeutics made up 0.03% of OrbiMed's portfolio in Q1 2026, its #109 holding.
  • OrbiMed first reported a position in VistaGen Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • OrbiMed's VistaGen Therapeutics position peaked at $45.6M in Q2 2021.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.